Frontlight ResearchEarly access
Active, not recruitingPhase 2
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Key facts
- Who runs it
- Sanofi
- Where
- Birmingham, Boston, Danbury, Denver, Gainesville, Hannibal, Hershey, Houston, Indianapolis, Los Angeles, Minneapolis, New York, Philadelphia, Phoenix, Portland, Sacramento, Salt Lake City, and Spartanburg, United StatesSee the 18 sitesAlso in 8 other countries, 22 sites
- Trial code
- NCT05897424
- EU 2023-508137-14-00
- U1111-1310-5249
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 185 people, planned
- Started
- 20 Jun 2024
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Treatments tested
- SAR447537
- Record updated
- 13 April 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Males or females 18-80 years of age, inclusive, at the time of screening
- Diagnosis of AATD
- Evidence of emphysema secondary to AATD
- FEV1 of ≥ 30% predicted at screening and post-bronchodilator FEV1/FVC<0.7
- Current non-smoking status
Who cannot take part
- Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
- Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
- On waiting list for lung or liver transplant
- Acute respiratory tract infection or COPD exacerbation within 4 weeks prior to or during screening
- Known or suspected allergy to components of SAR447537, A1PI or human IgG
- Active cancers or has a history of malignancy within 5 years prior to screening
- History of unstable cor pulmonale; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
- Uncontrolled diabetes mellitus despite adequate antidiabetic pharmacologic treatment with a screening HbA1c value ≥9%
- For newly identified participants
- Evidence of decompensated cirrhosis
Where in United States
Also in 8 other countries, 22 sites
- UAB Lung Health Center- Site Number : 105Birmingham, United States
- Brigham and Women's Hospital -75 Francis Street- Site Number : 131Boston, United States
- Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119Danbury, United States
- National Jewish Medical and Research Center- Site Number : 123Denver, United States
- University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101Gainesville, United States
- Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111Hannibal, United States
- Penn State Health Milton S. Hershey Medical Center- Site Number : 122Hershey, United States
- Houston Methodist Hospital- Site Number : 113Houston, United States
- Indiana University- Site Number : 127Indianapolis, United States
- David Geffen School of Medicine at UCLA- Site Number : 124Los Angeles, United States
- University of Minnesota-420 Delaware Str SE- Site Number : 125Minneapolis, United States
- Columbia University Irving Medical Center- Site Number : 104New York, United States
- Temple University Hospital - 3401 N Broad St- Site Number : 130Philadelphia, United States
- St Joseph's Hospital and Medical Center- Site Number : 126Phoenix, United States
- Oregon Health and Science University- Site Number : 117Portland, United States
- University of California Davis Medical Center- Site Number : 110Sacramento, United States
- University of Utah Health Care- Site Number : 106Salt Lake City, United States
- Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120Spartanburg, United States
About the trial
What the trial wants to find out
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
The group in the trial
- SAR447537 (INBRX-101)Treatment being tested
A1PI, Recombinant, Bivalent Fc Fusion Protein, in a solution for intravenous injection
Treatment: SAR447537
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
- Record updated
- 13 April 2026